Added to YB: 2026-05-15
Pitch date: 2026-05-13
NRXS [neutral]
NeurAxis, Inc.
-8.55%
current return
Author Info
Microcap Opportunities is a community dedicated to finding the best opportunities in the MicroCap space for US and Canadian listings primarily. Sign up for the newsletter.
Company Info
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Market Cap
$90.0M
Pitch Price
$7.95
Price Target
18.00 (+168%)
Dividend
N/A
EV/EBITDA
-11.74
P/E
-8.96
EV/Sales
19.46
Sector
Health Care Equipment and Supplies
Category
growth
NeurAxis Q1 2026: The KPIs Tell the Story
NRXS (earnings): Q1 rev $1.6M (+80% YoY), 7th straight quarter double-digit growth. ASP $1,017 (+33% YoY) toward $1,195 full price. 66 ordering accounts (+18% YoY), $24K rev/account (+53% YoY). Only 32% PA approval rate (up from 12% FY25); full coverage would've yielded $4.6M Q1 ($18.3M annualized) vs $6.4M current run rate. Breakeven at ~$15M annualized rev. VA orders ahead of expectations, adult RCT at Cleveland Clinic/Stanford launched. Cash $8M, burn improving to ~$1M/qtr. Going concern language persists pending 12-month self-sufficiency demonstration.
Read full article (5 min)